参麦注射液联合TE化疗方案治疗进展期乳腺癌的临床观察研究

王晶; 赵娜萍; 舒丽芯; 刘斌; 张婉露; 严天虹; 潘勇华; 张黎

留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

x 关闭永久关闭

应中央军委要求，2022年9月起，《药学实践杂志》将更名为《药学实践与服务》，双月刊，正文96页；2023年1月起，拟出版月刊，正文64页，数据库收录情况与原《药学实践杂志》相同。欢迎作者踊跃投稿！

参麦注射液联合TE化疗方案治疗进展期乳腺癌的临床观察研究

王晶, 赵娜萍, 舒丽芯, 刘斌, 张婉露, 严天虹, 潘勇华, 张黎

文章导航 > 药学实践与服务 > 2011 > 29(3): 184-187,203

王晶, 赵娜萍, 舒丽芯, 刘斌, 张婉露, 严天虹, 潘勇华, 张黎. 参麦注射液联合TE化疗方案治疗进展期乳腺癌的临床观察研究[J]. 药学实践与服务, 2011, 29(3): 184-187,203.

引用本文:

WANG Jing, ZHAO Na-ping, SHU Li-xin, LIU Bin, ZHANG Wan-lu, YAN Tian-hong, PAN Yong-hua, ZHANG Li. The clinical effect of TE chemotherapy regime, with Shenmai injection in the treatment of advanced breast cancer[J]. Journal of Pharmaceutical Practice and Service, 2011, 29(3): 184-187,203.

Citation:

WANG Jing, ZHAO Na-ping, SHU Li-xin, LIU Bin, ZHANG Wan-lu, YAN Tian-hong, PAN Yong-hua, ZHANG Li. The clinical effect of TE chemotherapy regime, with Shenmai injection in the treatment of advanced breast cancer[J]. Journal of Pharmaceutical Practice and Service, 2011, 29(3): 184-187,203.

参麦注射液联合TE化疗方案治疗进展期乳腺癌的临床观察研究

1.
第二军医大学长海医院药学部,上海 200433
2.
第二军医大学药学院,上海 200433
3.
中国人民解放军101医院药材科,江苏无锡 214044

基金项目: 上海高校选拔培养优秀青年教师科研专项基金(ejd09031,ejd09038).

The clinical effect of TE chemotherapy regime, with Shenmai injection in the treatment of advanced breast cancer

1.
Department of Pharmacy, Changhai Hospital, Second Military Medical University, Shanghai, 200433 China
2.
School of Pharmacy, Secondary Military Medical University, Shanghai 200433, China
3.
Department of Pharmacy, 101th Hospital of PLA, Wuxi 214044, China

摘要: 目的探讨参麦注射液联合新辅助化疗TE方案治疗乳腺癌的疗效和对乳腺癌患者生活质量的影响。方法我院收治的22例经病理证实的进展期乳腺癌患者,年龄34~72岁,随机分为试验组(参麦注射液联合TE治疗组)和对照组(单纯用TE化疗组)。对照组未给予任何中药注射液。对22例进展期乳腺癌患者的疗效、血常规指标及不良反应进行观察比较与分析,应用SPSS10.0统计软件进行统计学处理。结果可评价疗效病例22例,其中治疗组有效率(CR+PR) 54.55%,对照组有效率63.64%,两组之间差异无统计学意义(P＞0.05);临床获益率治疗组81.82%,对照组72.73%,两组之间差异无统计学意义(P＞0.05)。两组血液系统的不良反应与对照组相比,结果有统计学意义(P<0.05)。其他不良反应的发生率相似,两组差异无显著性(P＞0.05)。结论参麦注射液联合TE方案治疗乳腺癌疗效肯定,耐受性良好,加用参麦注射液可以改善肿瘤患者的生存质量,减轻化疗所致的血液学毒性及非血液学毒性,临床可推广应用。
- 参麦注射液 /
- 乳腺癌 /
- TE方案 /
- 临床观察
Abstract: Objective To investigate the efficacy of Shenmai injection combined TE chemotherapy regime in the treatment of breast cancer and the influence to the quality of life in breast cancer patient. Methods 22 patients with pathologically confirmed advanced breast cancer aged from 34 to 72 were randomly divided into experimental group (TE plus Shenmai injection treatment group) and the control group (only with TE chemotherapy group). The efficacy ,side effects and blood indices were observed and analyzed. All patients received two or more cycles of treatment. SPSS10.0 statistical software was used to statistical analysis. Results 22 cases could be evaluated.The effective rate of treatment group (CR+PR) was 54.55%, and the rate of control group was 63.64%. There was no significant difference between two groups (P>0.05); clinical benefit rate was 81.82% in treatment group, and 72.73% in control group, which had no significant difference between groups (P>0.05). The main adverse events in both groups were from the blood system. compared with the control group, which had statistically significant (P<0.05) between two groups. Other adverse reactions had the similar incidence in two groups and had not statistically significant (P>0.05). Conclusion TE Shenmai injection in the treatment of breast cancer was effective and well tolerated, plus Shenmai injection could improve the quality of life in cancer patients, reduce the chemotherapy-induced hematological toxicity and non-hematologic toxicity.
- Shenmai injection /
- breast cancer /
- TE program /
- clinical observation

[1]

李佩文,李学.中医肿瘤临床手册[M].上海:上海科学技术出版社,2006:145. [2] Mass HB. Endocrine therapy for advanced breast cancer [J].Breast Cancer Res Treat,1992,21:15. [3] 赵强,常英,潘靖.云硒冲剂对乳腺癌术后化疗患者免疫功能的影响[J].药学实践杂志. 2004,22(3):156. [4] 赵晓辉,郝春芳,佟仲生.紫杉醇单药每周方案治疗老年转移性乳腺癌的临床疗效观察[J].中华乳腺病杂志,2009,3(5):17. [5] 张代钊,余桂清,李佩文.癌症放化疗副反应的中医药防治研究[J].中医杂志,1994,35 (8):498. [6] 陈小红,高瑞兰,徐卫红,等.人参皂甙对红系,粒单系,巨核系细胞株的增殖及转录因子的诱导作用[J].中国中西医结合杂志,2001,21(1) :40. [7] 冯培芳,刘鲁明,沈玉英,等.参麦注射液对晚期癌症患者sIL-2R、LAK及NK细胞活性影响[J].中国中西医结合杂志,1995,15 (2):87. [8] 钱华,林胜友,刘鲁明,等.参麦注射液对肿瘤化疗的减毒作用[J].浙江中医学院学报,1995,19 (2):32.

[1]	张敏, 汪晓河, 周阳云, 石美智, 韩忻云, 韩向晖, 陈君君. 基于网络药理学和分子对接的苦参抗乳腺癌潜在机制研究 . 药学实践与服务, 2023, 41(12): 722-732. doi: 10.12206/j.issn.2097-2024.202302001
[2]	马小雨, 罗彩萍, 刘悦. 代谢组学在乳腺癌诊疗中应用的研究进展 . 药学实践与服务, 2023, 41(3): 139-145. doi: 10.12206/j.issn.2097-2024.202109112
[3]	雷碧黠, 张梦瑶, 陈晓锐, 梁蓓蓓, 解伟, 王华菁, 李博华. 表没食子儿茶素没食子酸酯联合曲妥珠单抗对HER2过表达乳腺癌细胞增殖的影响及其机制 . 药学实践与服务, 2022, 40(2): 136-142. doi: 10.12206/j.issn.1006-0111.202112035
[4]	周菊香, 王双英, 佘建涛, 曾贤良, 张继红. 肾衰竭对乳腺癌患者多西他赛暴露和不良反应的影响 . 药学实践与服务, 2022, 40(6): 571-575. doi: 10.12206/j.issn.2097-2024.202203068
[5]	王玮婷, 殷雪琴, 夏金娥, 张夏炎. 五味子乙素通过ROS介导内质网应激诱导人乳腺癌MDA-MB-231细胞凋亡的研究 . 药学实践与服务, 2021, 39(6): 499-503, 533. doi: 10.12206/j.issn.1006-0111.202106123
[6]	周瑾, 李盛建, 覃福礼, 杨新颖, 张晓琳, 赵亮. 月腺大戟素A通过干扰PKD1介导的MEK/ERK和PI3K/AKT信号通路抑制乳腺癌细胞增殖的研究 . 药学实践与服务, 2020, 38(3): 241-244, 276. doi: 10.12206/j.issn.1006-0111.201912008
[7]	曹青青, 李盛建, 李云青, 葛继云, 陈俊, 周瑾, 钱跹, 赵亮. 月腺大戟的化学成分及其乳腺癌细胞毒活性研究 . 药学实践与服务, 2019, 37(4): 309-313,317. doi: 10.3969/j.issn.1006-0111.2019.04.005
[8]	唐杰, 林厚文, 孙凡. 海绵来源的smenospongine诱导乳腺癌MCF7细胞凋亡机制研究 . 药学实践与服务, 2018, 36(5): 399-402,421. doi: 10.3969/j.issn.1006-0111.2018.05.004
[9]	齐婧. 阿瑞匹坦对乳腺癌AC方案化疗后中重度呕吐患者的二级预防 . 药学实践与服务, 2017, 35(2): 158-160,181. doi: 10.3969/j.issn.1006-0111.2017.02.015
[10]	胡兰兰, 孔飞飞, 郭良君. 静脉滴注参麦注射液致疑似罕见不良反应1例 . 药学实践与服务, 2015, 33(2): 190-190. doi: 10.3969/j.issn.1006-0111.2015.02.027
[11]	黄景彬, 钟延强. 乳腺癌靶向治疗的新策略 . 药学实践与服务, 2011, 29(5): 324-327.
[12]	闫青, 邓璐. 双侧风池注射参麦注射液配合常规方法治疗脑干梗塞45例 . 药学实践与服务, 2008, (5): 353-353,356.
[13]	张琳, 吕建峰. 醋酸甲羟孕酮改善中晚期癌症患者生活质量的临床观察 . 药学实践与服务, 2006, (3): 158-159.
[14]	周文丽, 高源, 员燕. 平甲灵片的制备及临床疗效观察 . 药学实践与服务, 2004, (2): 120-121.
[15]	赵强, 常英, 潘靖, 张军东. 云硒冲剂对乳腺癌术后化疗患者免疫功能的影响 . 药学实践与服务, 2004, (3): 156-157.
[16]	邓莉萍, 董吁钢, 何建桂. 国产与进口乌拉地尔的临床疗效观察 . 药学实践与服务, 2002, (3): 152-154.
[17]	王军, 王绍庭. 通络消刺丸治疗腰腿痛临床观察 . 药学实践与服务, 2001, (2): 75-75,70.
[18]	魏立明, 徐利. 牙髓尖周疾病空管药物疗法的临床观察 . 药学实践与服务, 2000, (1): 8-9.
[19]	徐声济, 郑庆华, 王一敏. 复方磺胺嘧啶锌膜剂的制备及应用 . 药学实践与服务, 1995, (2): 96-97.
[20]	郭涛, 史国兵, 马燕. 益康口服液的研制及临床观察 . 药学实践与服务, 1995, (2): 100-102.

点击查看大图

计量

文章访问数: 2516
HTML全文浏览量: 178
PDF下载量: 173
被引次数: 0

参麦注射液联合TE化疗方案治疗进展期乳腺癌的临床观察研究

1. 第二军医大学长海医院药学部,上海 200433

2. 第二军医大学药学院,上海 200433

3. 中国人民解放军101医院药材科,江苏无锡 214044

基金项目: 上海高校选拔培养优秀青年教师科研专项基金(ejd09031,ejd09038).

收稿日期: 2010-06-22
修回日期: 2011-01-11

关键词:

参麦注射液 /

乳腺癌 /

TE方案 /

临床观察

摘要: 目的探讨参麦注射液联合新辅助化疗TE方案治疗乳腺癌的疗效和对乳腺癌患者生活质量的影响。方法我院收治的22例经病理证实的进展期乳腺癌患者,年龄34~72岁,随机分为试验组(参麦注射液联合TE治疗组)和对照组(单纯用TE化疗组)。对照组未给予任何中药注射液。对22例进展期乳腺癌患者的疗效、血常规指标及不良反应进行观察比较与分析,应用SPSS10.0统计软件进行统计学处理。结果可评价疗效病例22例,其中治疗组有效率(CR+PR) 54.55%,对照组有效率63.64%,两组之间差异无统计学意义(P＞0.05);临床获益率治疗组81.82%,对照组72.73%,两组之间差异无统计学意义(P＞0.05)。两组血液系统的不良反应与对照组相比,结果有统计学意义(P<0.05)。其他不良反应的发生率相似,两组差异无显著性(P＞0.05)。结论参麦注射液联合TE方案治疗乳腺癌疗效肯定,耐受性良好,加用参麦注射液可以改善肿瘤患者的生存质量,减轻化疗所致的血液学毒性及非血液学毒性,临床可推广应用。

English Abstract

The clinical effect of TE chemotherapy regime, with Shenmai injection in the treatment of advanced breast cancer

1. Department of Pharmacy, Changhai Hospital, Second Military Medical University, Shanghai, 200433 China

2. School of Pharmacy, Secondary Military Medical University, Shanghai 200433, China

3. Department of Pharmacy, 101th Hospital of PLA, Wuxi 214044, China

Received Date: 2010-06-22
Rev Recd Date: 2011-01-11

Keywords:

Abstract: Objective To investigate the efficacy of Shenmai injection combined TE chemotherapy regime in the treatment of breast cancer and the influence to the quality of life in breast cancer patient. Methods 22 patients with pathologically confirmed advanced breast cancer aged from 34 to 72 were randomly divided into experimental group (TE plus Shenmai injection treatment group) and the control group (only with TE chemotherapy group). The efficacy ,side effects and blood indices were observed and analyzed. All patients received two or more cycles of treatment. SPSS10.0 statistical software was used to statistical analysis. Results 22 cases could be evaluated.The effective rate of treatment group (CR+PR) was 54.55%, and the rate of control group was 63.64%. There was no significant difference between two groups (P>0.05); clinical benefit rate was 81.82% in treatment group, and 72.73% in control group, which had no significant difference between groups (P>0.05). The main adverse events in both groups were from the blood system. compared with the control group, which had statistically significant (P<0.05) between two groups. Other adverse reactions had the similar incidence in two groups and had not statistically significant (P>0.05). Conclusion TE Shenmai injection in the treatment of breast cancer was effective and well tolerated, plus Shenmai injection could improve the quality of life in cancer patients, reduce the chemotherapy-induced hematological toxicity and non-hematologic toxicity.

引用本文:

Citation:

WANG Jing, ZHAO Na-ping, SHU Li-xin, LIU Bin, ZHANG Wan-lu, YAN Tian-hong, PAN Yong-hua, ZHANG Li. The clinical effect of TE chemotherapy regime, with Shenmai injection in the treatment of advanced breast cancer[J]. Journal of Pharmaceutical Practice and Service, 2011, 29(3): 184-187,203.

全文HTML

参考文献 (1)

下载: 全尺寸图片幻灯片

返回文章

用微信扫码二维码

分享至好友和朋友圈

主管、主办: 中国人民解放军海军军医大学地址: 上海市杨浦区国和路325号邮政编码: 200433

电话: （021）81871324,81871397 E-mail: yxsjzzs@163.com

网站备案号沪ICP备05003363号-1

本系统由北京仁和汇智信息技术有限公司开发

留言板

参麦注射液联合TE化疗方案治疗进展期乳腺癌的临床观察研究

The clinical effect of TE chemotherapy regime, with Shenmai injection in the treatment of advanced breast cancer

计量

出版历程

参麦注射液联合TE化疗方案治疗进展期乳腺癌的临床观察研究

1. 第二军医大学长海医院药学部,上海 200433 2. 第二军医大学药学院,上海 200433 3. 中国人民解放军101医院药材科,江苏 无锡 214044

English Abstract

The clinical effect of TE chemotherapy regime, with Shenmai injection in the treatment of advanced breast cancer

1. Department of Pharmacy, Changhai Hospital, Second Military Medical University, Shanghai, 200433 China 2. School of Pharmacy, Secondary Military Medical University, Shanghai 200433, China 3. Department of Pharmacy, 101th Hospital of PLA, Wuxi 214044, China

全文HTML

目录

1. 第二军医大学长海医院药学部,上海 200433

2. 第二军医大学药学院,上海 200433

3. 中国人民解放军101医院药材科,江苏无锡 214044

1. Department of Pharmacy, Changhai Hospital, Second Military Medical University, Shanghai, 200433 China

2. School of Pharmacy, Secondary Military Medical University, Shanghai 200433, China

3. Department of Pharmacy, 101th Hospital of PLA, Wuxi 214044, China